SYRE (Spyre Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SYRE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-09-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-09-03 | Heidy King-Jones | See Remarks | MIXED | — | — |
| 2026-08-10 | Jeffrey W. Albers | Director | MIXED | — | — |
| 2026-08-05 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-08-05 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-07-02 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-07-02 | Sheldon Sloan | Chief Medical Officer | MIXED | — | — |
| 2026-07-02 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-06-26 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-06-23 | MICHAEL THOMAS HENDERSON | Director | Sell | — | — |
| 2026-06-23 | Fairmount Funds Management LLC | Director | MIXED | — | — |
| 2026-06-03 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-06-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-06-03 | Sheldon Sloan | Chief Medical Officer | MIXED | — | — |
| 2026-05-29 | MICHAEL THOMAS HENDERSON | Director | A | — | — |
| 2026-05-29 | Tomas Kiselak | Director | A | — | — |
| 2026-05-29 | Laurie Stelzer | Director | A | — | — |
| 2026-05-29 | Mark C. McKenna | Director | A | — | — |
| 2026-05-29 | Jeffrey W. Albers | Director | A | — | — |
| 2026-05-29 | Sandra Milligan | Director | A | — | — |
| 2026-05-08 | MICHAEL THOMAS HENDERSON | Director | Sell | — | — |
| 2026-05-01 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-05-01 | Sheldon Sloan | Chief Medical Officer | MIXED | — | — |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-04-03 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-04-03 | Sheldon Sloan | Chief Medical Officer | MIXED | — | — |
| 2026-04-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-03-03 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-03-03 | Scott L Burrows | Chief Financial Officer | MIXED | — | — |
| 2026-02-04 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2026-01-23 | MICHAEL THOMAS HENDERSON | Director | J | — | — |
| 2026-01-13 | Sheldon Sloan | Chief Medical Officer | A | — | — |
| 2026-01-13 | Cameron Turtle | Chief Executive Officer | A | — | — |
| 2026-01-13 | Heidy King-Jones | See Remarks | A | — | — |
| 2026-01-13 | Scott L Burrows | Chief Financial Officer | A | — | — |
| 2026-01-06 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2025-12-03 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2025-11-05 | Cameron Turtle | Chief Executive Officer | Sell | — | — |
| 2025-09-03 | Scott L Burrows | Chief Financial Officer | Sell | — | — |
| 2025-06-02 | Laurie Stelzer | Director | A | — | — |
| 2025-06-02 | Mark C. McKenna | Director | A | — | — |
| 2025-06-02 | Jeffrey W. Albers | Director | A | — | — |
| 2025-06-02 | Sandra Milligan | Director | A | — | — |
| 2025-06-02 | MICHAEL THOMAS HENDERSON | Director | A | — | — |
| 2025-06-02 | Fairmount Healthcare Fund II L.P. | Director | A | — | — |
| 2025-01-17 | Scott L Burrows | Chief Financial Officer | A | — | — |
| 2025-01-17 | Heidy King-Jones | See Remarks | A | — | — |
| 2025-01-17 | Cameron Turtle | Chief Executive Officer | A | — | — |
| 2025-01-17 | Sheldon Sloan | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 565,040 | — |
| — | Director | 406,038 | — |
| — | Director | 406,038 | — |
| — | Chief Financial Officer | 100,210 | — |
| — | Director | 68,606 | — |
| — | Director | 24,360 | — |
| — | See Remarks | 3,245 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SYRE quote page; the site-wide leaderboard is on the insider transactions hub.